Pharmacogenomic Informed Statin Prescribing (NCT06568601)
Reducing Veterans' Risk of Atherosclerotic Cardiovascular Disease Through Pharmacogenomics Informed Statin Prescribing
🩺 Plain-English Summary (8th-Grade Level)
Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins. This gap in patient's use of statins limits the full impact of these effective medications resulting in higher cholesterol levels and CVD risk. The main barriers to using statins are patients' perceived lack of benefit, excess risk of statin toxicity as well as their misperceptions of their CVD risk. Statin pharmacogenomic testing - an application of precision medicine - is a readily available, feasible, and inexpensive intervention that addresses this barrier by using genetic testing to identify the nearly 1 out of 2 patients with enhanced benefit and/or reduced risk of statin toxicity or increased risk for CVD. By communicating statin pharmacogenomic test results to Veterans at high-risk for CVD not taking statin therapy, the investigators aim to improve patients' perceptions of their risk of CVD and statins and, in turn, their acceptance of and adherence to statins to reduce their cholesterol levels and CVD risk.
Who can join: Review the eligibility criteria below.
Location: Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
Age range: 40 Years to 75 Years
🧪 Interventions in This Study
- Pharmacogenetic and polygenic risk testing (GENETIC)
- Active control (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
- Durham VA Medical Center, Durham, NC — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 286-0411
Email: deepak.voora@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hypercholesterolemia
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension — Daphne, Alabama
- Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy — Baltimore, Maryland
- Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile — Addison, Illinois
- Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia — Clearwater, Florida
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia — Anniston, Alabama
- Causes and Natural History of Dyslipidemias — Bethesda, Maryland
Explore by condition: All Hypercholesterolemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.